.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
Recent clinical data suggests that lenvatinib plus pembrolizumab efficacy extends to difficult-to-treat nonendometrioid endometrial cancers. A retrospective study at Jichi Medical University Hospital evaluated clinical outcomes for patients with recurrent disease. Specifically, researchers examined rare variants like carcinosarcoma and mesonephric-like adenocarcinoma. Although these subtypes often carry a poor prognosis, the combination therapy showed meaningful clinical activity.
The study involved 26 patients, including 11 with nonendometrioid carcinoma. Notably, the objective response rate for the nonendometrioid group reached 33.3%. Furthermore, the disease control rate was exceptionally high at 90.9%. In comparison, the endometrioid group had a response rate of 22.2% and a disease control rate of 100%.
Median progression-free survival was 6.2 months for nonendometrioid types. However, patients with endometrioid histology achieved a longer median survival of 11.5 months. In addition, the median overall survival for nonendometrioid cases was 12.0 months. Consequently, these findings highlight the potential of this regimen in managing aggressive histological variants.
Hypertension was the most frequent adverse event, occurring in 92.3% of patients. Moreover, hypothyroidism affected 65.4% of the cohort. As a result, histology and platinum-free intervals were not identified as independent prognostic factors for survival. Therefore, the treatment benefit remains consistent across various clinical subgroups. Further accumulation of patient data is warranted to validate these results in uncommon histologic types.
Research indicates an objective response rate of 33.3% and a disease control rate of 90.9% for nonendometrioid subtypes, including carcinosarcoma and mesonephric-like adenocarcinoma.
The most common adverse events are hypertension, which affects over 90% of patients, and hypothyroidism, seen in approximately 65% of cases.
Disclaimer: This content is for informational and educational purposes only. It is not intended as medical advice or as a substitute for professional healthcare guidance. Refer to the latest local and national guidelines for clinical practice.
References
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
A study reveals the efficacy of lenvatinib plus pembrolizumab for recurrent nonendometrioid endometrial cancer, showing a 33.3% objective response rate....
4 months ago
Andhra Pradesh reported 10 new Covid-19 cases, taking the state tally to 49 while deaths remain at four. With 24 patients hospitalized and 16 under home isolation, the Health Department has intensified monitoring. Medical professionals should review regional distribution, diagnostic protocols, and management plans.
Today
An 11-year Swedish registry study of 618 uterine sarcoma patients found that minimally invasive surgery yielded survival comparable to open surgery in early stages. However, adjuvant chemotherapy conferred no survival benefit in localized or advanced disease, highlighting stage and histology as key outcomes.
3 days back
A cross-sectional study evaluates post-intensive care syndrome in cardiac patients 2-4 weeks post-ICU discharge, highlighting cognitive, psychological, and functional impairments and the need for structured multidisciplinary rehabilitation.
3 days back
Anterior cruciate ligament reconstruction failure lacks uniform definition. A narrative review proposes an integrative framework incorporating objective and subjective instability, persistent pain, restricted motion, graft rupture, and secondary meniscal injury to standardize clinical reporting.
3 days back
With World Obesity Atlas data warning that over 41 million Indian children are overweight or obese, ICMR and NIN have unveiled a 10-point policy roadmap. The initiative calls for mandatory front-of-pack labeling, HFSS taxes, strict marketing bans, and healthier school environments to curb non-communicable diseases.
Today
